Lixte Biotechnology Enters Material Definitive Agreement

Ticker: LIXT · Form: 8-K · Filed: Mar 14, 2025 · CIK: 1335105

Lixte Biotechnology Holdings, INC. 8-K Filing Summary
FieldDetail
CompanyLixte Biotechnology Holdings, INC. (LIXT)
Form Type8-K
Filed DateMar 14, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: material-definitive-agreement, filing

Related Tickers: LIXT

TL;DR

LIXT signed a big deal on March 11th, 8-K filed.

AI Summary

Lixte Biotechnology Holdings, Inc. entered into a material definitive agreement on March 11, 2025. The company, incorporated in Delaware with its principal executive offices in Pasadena, California, filed an 8-K report detailing this agreement. The filing also includes financial statements and exhibits related to the event.

Why It Matters

This filing indicates a significant new development or contract for Lixte Biotechnology, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — Entering into material definitive agreements can carry inherent risks related to the terms, execution, and potential impact on the company's financial health.

Key Players & Entities

FAQ

What type of material definitive agreement did Lixte Biotechnology Holdings, Inc. enter into?

The filing does not specify the exact nature of the material definitive agreement, only that one was entered into on March 11, 2025.

What is the principal executive office address for Lixte Biotechnology Holdings, Inc.?

The principal executive offices are located at 680 East Colorado Boulevard, Suite 180, Pasadena, California 91101.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on March 11, 2025.

What is the SEC File Number for Lixte Biotechnology Holdings, Inc.?

The SEC File Number is 001-39717.

What is the IRS Employer Identification Number for Lixte Biotechnology Holdings, Inc.?

The IRS Employer Identification Number is 20-2903526.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 14, 2025 regarding LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing